Abstract
Ro 41-3399 is a novel orally active ester of Ro 40-6890, an aminothiazolyl cephalosporin with potent in vitro activities against commonly encountered aerobic gram-positive bacteria (streptococci and methicillin-susceptible staphylococci) and gram-negative bacteria (members of the family Enterobacteriaceae, haemophili, meningococci, and gonococci). In terms of the MICs determined by the methods recommended by the National Committee for Clinical Laboratory Standards, for 50 and 90% of gram-positive organisms, the water-soluble free carboxylic acid Ro 40-6890 proved to be at least as active as or two- to fourfold more active than cefpodoxime, cefuroxime, cefaclor, amoxicillin, amoxicillin-clavulanic acid, and ceftriaxone; against aerobic gram-negative organisms, Ro 40-6890 was usually two- to fourfold more active than cefpodoxime, the next most potent of the oral drugs under comparison, but remained usually two- to fourfold weaker than ceftriaxone. Ro 40-6890 showed a high affinity for the essential penicillin-binding proteins of susceptible bacteria and was resistant to hydrolysis by a broad array of beta-lactamases. Ro 41-3399 bopentil was well absorbed in mice when administered by oral gavage and proved effective in several experimental bacterial infections. Further studies with Ro 41-3399 and Ro 40-6890 are in progress.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Angehrn P., Hohl P., Then R. L. In vitro antibacterial properties of cefetamet and in vivo activity of its orally absorbable ester derivative, cefetamet pivoxil. Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):536–543. doi: 10.1007/BF01967476. [DOI] [PubMed] [Google Scholar]
- Bush K. Characterization of beta-lactamases. Antimicrob Agents Chemother. 1989 Mar;33(3):259–263. doi: 10.1128/aac.33.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cullmann W., Dick W. Cefpodoxime: comparable evaluation with other orally available cephalosporins. With a note on the role of beta-lactamases. Zentralbl Bakteriol. 1990 Sep;273(4):501–517. doi: 10.1016/s0934-8840(11)80458-5. [DOI] [PubMed] [Google Scholar]
- Fujimoto K., Ishihara S., Yanagisawa H., Ide J., Nakayama E., Nakao H., Sugawara S., Iwata M. Studies on orally active cephalosporin esters. J Antibiot (Tokyo) 1987 Mar;40(3):370–384. doi: 10.7164/antibiotics.40.370. [DOI] [PubMed] [Google Scholar]
- Harding S. M., Williams P. E., Ayrton J. Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother. 1984 Jan;25(1):78–82. doi: 10.1128/aac.25.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hubschwerlen C., Charnas R., Angehrn P., Furlenmeier A., Graser T., Montavon M. Orally active 2-(alkyloxycarbonyl)-2-alkylideneethyl esters of cephalosporins. J Antibiot (Tokyo) 1992 Aug;45(8):1358–1364. doi: 10.7164/antibiotics.45.1358. [DOI] [PubMed] [Google Scholar]
- Kitzis M. D., Liassine N., Ferré B., Gutmann L., Acar J. F., Goldstein F. In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1990 Sep;34(9):1783–1786. doi: 10.1128/aac.34.9.1783. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Utsui Y., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Jul;31(7):1085–1092. doi: 10.1128/aac.31.7.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]